Breaking Ground: New Alzheimer’s Treatment Launches!

The Alzheimer’s Treatment Briefing

Weekly roundup of the most important developments in Alzheimer’s care and research
Coverage period: September 30–October 6, 2025 (U.S.)


Top stories (ranked)

  1. Leqembi’s at‑home autoinjector officially launches in the U.S. today (Oct 6)
  • What’s new
    • Eisai/Biogen’s once‑weekly, under‑the‑skin maintenance version of lecanemab (Leqembi IQLIK) is now available to U.S. patients who’ve completed the initial 18‑month IV phase. The list price for the maintenance autoinjector is $19,500 per year. Safety monitoring (including scheduled brain MRIs) still applies. (reuters.com)
  • Why this matters
    • Easier to take: Home injections can cut travel and chair time at infusion centers, which may widen access—especially for people far from large clinics. (reuters.com)
    • Same drug, new format: It’s another way to keep amyloid low after the IV “clean‑out” phase; it doesn’t remove the need for MRI checks early on. (reuters.com)
    • Planning ahead: Expect care teams to focus on teaching safe self‑injection, scheduling MRIs, and confirming risk counseling before switching. Company support programs and patient navigators are being promoted alongside the launch. (investors.biogen.com)
  1. What today’s launch means for costs and coverage—in plain English
  • What’s new
    • Medicare still covers anti‑amyloid drugs like Leqembi for people with early Alzheimer’s who meet criteria and whose clinician participates in a simple registry that tracks real‑world outcomes. Under Original Medicare Part B, patients typically pay 20% coinsurance after the deductible; Medicare Advantage plans mirror Part B benefits. Exact coverage for the at‑home format depends on how your plan and provider bill it, so patients should confirm with their clinic and plan. (cms.gov)
  • Why this matters
    • No surprises: Understanding coinsurance, MRI costs, and registry requirements up front helps families budget and avoid delays in switching to the at‑home injector. (cms.gov)
  1. Safety reminder as more people start or switch therapy
  • What’s new
    • Regulators recently emphasized earlier MRI monitoring to catch brain swelling (ARIA) sooner in people starting Leqembi—advising a scan before the third infusion, not just later in treatment. As more clinics move patients to maintenance dosing (IV monthly or weekly at‑home injections), teams are reinforcing MRI schedules and symptom reporting. (reuters.com)
  • Why this matters
    • Catching problems early: Most ARIA is mild and temporary, but early scans and quick reporting of headaches, confusion, or visual changes help keep treatment safe. (reuters.com)
  1. Fresh lab clue to target early brain “overactivity” in Alzheimer’s
  • What’s new
    • A new preprint (Oct 3) points to a protein called Pyk2 as a key switch in early memory‑center overactivity and synapse loss triggered by toxic amyloid fragments—suggesting a possible drug target to calm circuits before damage spreads. This is early, lab‑based work (not a human trial) but adds weight to “protect the synapse” strategies. (arxiv.org)
  • Why this matters
    • Beyond plaques: Today’s drugs clear amyloid; tomorrow’s combinations may also protect synapses and tame harmful brain overactivity. This paper helps map where to aim. (arxiv.org)

Quick takes (this week)

  • Practical help at launch: Eisai/Biogen say patient navigators and injection‑training support are available for eligible families transitioning to the at‑home autoinjector. Ask your clinic to connect you if needed. (investors.biogen.com)
  • Expect local rollouts to vary: Health systems will spend the next few weeks fine‑tuning training, MRI slots, and billing workflows for the at‑home option. Your start date may depend on your center’s readiness. (reuters.com)

What this means for patients and caregivers (plain language)

  • If you’re doing well after 18 months of IV Leqembi, you may now have a simpler, at‑home option to keep amyloid down. It’s weekly and still needs regular safety checks. (reuters.com)
  • Costs and coverage vary by plan. Under Medicare, most people pay 20% coinsurance for Part B drugs after the deductible, and your doctor must log basic information in a registry. Confirm details with your clinic and plan—especially for the at‑home format. (cms.gov)
  • New ideas are moving through the pipeline. Lab findings this week point to fresh targets that could one day pair with today’s amyloid‑lowering drugs. (arxiv.org)

FAQs

  • Who might switch to the at‑home autoinjector first?

    • People in the earliest stage of Alzheimer’s who have completed the 18‑month IV phase and are stable on therapy. Your clinician will confirm timing, training, and MRI plans. (reuters.com)
  • Is the at‑home version safer?

    • The main risks (like ARIA) are similar. What changes is convenience—not the need for close monitoring and scheduled MRIs, especially early in treatment. (reuters.com)
  • How do we get cost help?

    • Ask about plan benefits, supplemental insurance, and company programs that offer navigation and, for qualifying patients, financial assistance. Your clinic can start that process. (investors.biogen.com)

If you want us to track additional therapies (anti‑tau drugs, GLP‑1s, vaccines) in coming editions, tell us and we’ll add them to the watchlist.